Zhitong Finance App News, Jingfang Pharmaceutical-B (02595.HK) announced that a registered phase III trial (GFH375X1301) of oral administration of the KRAS G12D (ON/OFF) inhibitor GFH375 to treat patients with KRAS G12D mutant metastatic pancreatic cancer () has been initiated at Peking University Cancer Hospital. Currently, GFH375 is in the first tier of oral KRAS G12D inhibitors in the world. A number of GFH375 (known as VS-7375 outside of China) single drugs and combination therapies are being clinically explored in China (led by Jingfang) and overseas (led by Jinfang partner Verastem Oncology), including GFH375 combined chemotherapy (albumin paclitaxel and gemcitabine, AG) for first-line treatment of advanced pancreatic ductal adenocarcinoma (PDAC); in addition, GFH375/VS-7375 has obtained FDA Fast Track Eligibility Identify and treat patients with locally advanced and metastatic KRAS G12D mutant PDAC in all lines.

Zhitong Finance App News, Jingfang Pharmaceutical-B (02595.HK) announced that a registered phase III trial (GFH375X1301) of oral administration of the KRAS G12D (ON/OFF) inhibitor GFH375 to treat patients with KRAS G12D mutant metastatic pancreatic cancer () has been initiated at Peking University Cancer Hospital. Currently, GFH375 is in the first tier of oral KRAS G12D inhibitors in the world. A number of GFH375 (known as VS-7375 outside of China) single drugs and combination therapies are being clinically explored in China (led by Jingfang) and overseas (led by Jinfang partner Verastem Oncology), including GFH375 combined chemotherapy (albumin paclitaxel and gemcitabine, AG) for first-line treatment of advanced pancreatic ductal adenocarcinoma (PDAC); in addition, GFH375/VS-7375 has obtained FDA Fast Track Eligibility Identify and treat patients with locally advanced and metastatic KRAS G12D mutant PDAC in all lines.